News | Treatment Planning | September 05, 2019

First Clinical Monte Carlo Photon Dose Planning Conducted in RayStation

Heidelberg University Hospital treats cervical cancer patient with lymph node involvement using fast Monte Carlo dose calculations of RayStation

First Clinical Monte Carlo Photon Dose Planning Conducted in RayStation

September 5, 2019 — Heidelberg University Hospital, Germany, has treated its first patient using Monte Carlo photon dose planning in RayStation. The decision to go clinical was made after a thorough validation of the functionality. The first patient, who has cervical cancer involving the lymph nodes, was recently treated.

In April 2018, RayStation was selected for particle therapy treatment planning in a joint decision by clinicians and researchers at Heidelberg Ion Beam Therapy Center (HIT), Heidelberg University Hospital and the German Cancer Research Center (DKFZ). Heidelberg University Hospital extended its RayStation installation for photon beam therapy in July 2018, strengthening the existing partnership with RaySearch. The order reflects the hospital’s aim of adopting RayStation as its sole treatment planning system, consolidating several legacy systems.

A vital feature in a treatment planning system is the ability to calculate the radiation dose a patient would receive during a proposed treatment. This involves modeling the components of the treatment machine, the patient’s anatomy and the radiation beam itself. RayStation 8B introduced the Monte Carlo dose calculation method for photon radiation, based on the well-known Monte Carlo algorithm, which is widely regarded as the gold standard for dose calculation.

The drawback of Monte Carlo has traditionally been prohibitively long calculation times. However, the graphics processing unit (GPU)-based dose engine in RayStation overcomes this limitation. As an example, the dose for a dual-arc volumetric modulated arc therapy (VMAT) plan can be computed in less than 30 seconds – faster than any other system on the market, according to RayStation. The Monte Carlo dose engine can also be used to calculate dose during optimization of the treatment plan, which can improve accuracy.

Heidelberg University is the oldest university in Germany; its first medical lectures were held in 1388. Today, Heidelberg University Hospital is one of the largest and most prestigious medical centers in Europe, with a reputation based on excellent patient care, research and teaching. The hospital offers inpatients and outpatients innovative and effective treatment for all complex diseases. Modern buildings with state-of-the-art equipment deliver medical care to the highest international standards. Proximity and interlinking of the specialist departments benefit the patient, with interdisciplinary cooperation ensuring optimal treatment.

Bernhard Rhein, Ph.D., and medical physicist at Heidelberg University Hospital, said, “The Monte Carlo dose engine has resulted in more accurate dose computation, especially for bone structures and the borders between tissues of differing densities. This is a significant step forward in bringing the calculated dose closer to the actual dose.”

For more information: www.raysearchlabs.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...